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HemodialysisMalnutrition and chronic inflammation in dialysis patients negatively impact their survival
prognosis, and nutrients, such as omega-3 oils, are postulated to reduce proinflammatory
response. In this randomized, double-blind, multicenter, placebo-controlled trial, we
investigated the effects of flaxseed oil (FO) on the inflammatory state of patients with
chronic renal failure undergoing renal replacement therapy with hemodialysis (HD). We
hypothesized that FO supplementation lowers C-reactive protein (CRP) levels. One hundred
sixty patients with chronic renal failure who received HD therapy of 3 dialysis units over a
3-month period in South Brazil were included. The patients received blind doses of FO (1 g
twiceaday) andplacebo (mineral oil, 1 g twiceaday) for aperiodof120days. Inflammationwas
observed in 89 patients (61%) at the beginning of the study. There was a correlation between
CRP and the bodymass index (Rs = 0.22; P = .022) and high-density lipoprotein cholesterol (Rs =
−0.23; P = .032), and the CRP levels decreased significantly over time in the group that received
FO compared with the control group (P < .001). During the study period, 33.3% of the FO group
changed from an inflamed to a not-inflamed category, whereas only 16.9% changed in the
mineral oil group (P = .04).We conclude that the administration of FO decreases the CRP levels
and that inflammation in HD patients appears to be correlated to their body mass index and
reduced high-density lipoprotein cholesterol levels. Studies with a larger number of patients
and over a longer duration are necessary to corroborate these findings.
© 2012 Elsevier Inc.   Open access under the Elsevier OA license.Inflammation
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Human1. Introduction
A significant proportion of patients undergoing renal replace-
ment therapy (RRT) with hemodialysis (HD) or peritoneal
dialysis present amicroinflammatory state, which is clinically
detected by increased levels of C-reactive protein (CRP) and, Body mass index; CRP, C
, High-density lipoprotein
, Omega-3; n-6, Omega-6
.br (J.R.N. Lemos).
r the Elsevier OA license.other inflammatory markers, mainly interleukin 1 and
interleukin 6 [1,2]. This proinflammatory state is predictive
of higher mortality levels and is associated with the malnu-
trition, inflammation, and atherosclerosis syndrome [3] and
other factors, including the dialysis treatment itself [4−6].
Moreover, several uremic patients present a deficiency of-reactive protein; DHA, Docosahexaenoic; EPA, Eicosapentaenoic
; HDL-c, High-density lipoprotein cholesterol; IL, Interleukin; LDL,
; RRT, Renal replacement therapy; TNF-α, Tumor necrosis factor α;
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that may produce or worsen the proinflammatory state [7].
Animal experiments and human clinical trials have sug-
gested that fishoils,which containpolyunsaturated fatty acids
such as eicosapentaenoic acid (EPA) (20:5n3) and docosahex-
aenoic acid (DHA) (22:6n3), have anti-inflammatory properties.
Some evidence includes the inhibition of proinflammatory
eicosanoids derived from n-6 fatty acids, such as arachidonic
fatty acid (20:4n6), and a decreased in the activity from
proinflammatory cytokines [8−11]. These findings were fur-
ther corroborated by Ewers et al [12] in a study in which an
adult HD population supplemented with unsaturated fat
showed beneficial effects in terms of weight gain and
decreased levels of CRP. Bowden et al [13] obtained similar
results for the CRP levels in patients supplemented with fish
oil. However, themain difficulties for the clinical use of fish oil
are the sensorial intolerance and the high cost, leading to a
high incidence of discontinuation even before the therapeutic
effects occur [14]. Other oils are described as having similar
effects; nevertheless, few studies have been conducted to
evaluate the action of EPA and DHA precursors, such as α-
linolenic acid (αLNA), which are present in high quantities in
somevegetable oils. Flaxseed oil (FO) (Linumusitatissimum) does
not contain EPA and DHA fatty acids, but it is the only oil of
plant origin known to have significant amounts of αLNA and is
considered to be the seed oil with the highest concentration of
this fatty acid [15]. As the concentration and proportion of the
omega-3 (n-3) and omega-6 (n-6) fatty acids are considered
ideal, FO has been tested in clinical trials that have described a
potential beneficial effect for certain disorders, such as
dyslipidemia and cardiovascular disease [16−19]. However,
there are no studies that have tested FO in patients with end-
stage renal disease undergoing RRT with HD.
Considering its characteristics and the lack of significant
side effects as well as good acceptability, we undertook the
present randomized clinical trial to test the hypothesis that
therapeutic doses of FO could lead to a decrease in the CRP
levels in patients undergoing RRT with HD.2. Methods and materials
2.1. Patients and study design
One hundred sixty patients with terminal renal failure who
were undergoing chronic HD from 3 dialysis units in the
southern state of Rio Grande do Sul, Brazil, were included in a
double-blind, randomized clinical trial. Informed consent was
obtained by all patients. The following inclusion criteria were
observed: (a) 18 years old; (b) RRT with HD for at least 90 days;
(c) absence of known infection, active inflammation, malig-
nancy, HIV seropositivity, and autoimmune disease; (d)
absence of intravenous dialysis catheters; (e) no transplants;
and (f) acceptance of participation.
2.2. Methods
The demographic variables and laboratory data included the
age, sex, race, time under RRT, primary renal disease, CRP,
total cholesterol and high-density lipoprotein (HDL), triglyc-erides, complete blood counts, calcium, phosphorus, parathy-
roid hormone, alanine aminotransferase, anti–hepatitis C
antibodies, and hepatitis B surface antigen. The urea reduc-
tion rate, Kt/V, and calcium-phosphorus product were also
calculated. C-reactive protein was measured using the Cardi-
oPhase hsCRP reagent method (Dade Behring, Marburg,
Germany). Other measurements were performed using stan-
dard clinical laboratory methods.
The patients included were randomized into 2 treatment
groups: a FO group, receiving 1.0 g of FO plus α-tocopherol
(3.5 mg) twice a day, and the control mineral oil (MO) group,
receiving 1.0 g of MO + 3.5 mg of α-tocopherol twice a day. The
FO and placebo capsules were visually identical. The patients
in both groups were instructed to take the capsules for 120
days; adherence was assessed by counting the remaining
capsules every 30 days. The laboratory data were collected at
baseline, 60, and 120 days after the beginning of therapy. The
serum cholesterol and fractions and triglycerides were
measured at baseline and 120 days in the 84 patients who
could fast for the sampling.
The patients were considered to have inflammation if the
serum CRP is 5.1 mg/L [32]. Those patients unable to tolerate
intervention or who developed any of the exclusion criteria
during the study were excluded. The patients were also
analyzed according to intention to treat. The study was
approved by the research ethics committee of the coordinat-
ing center (Hospital de Clínicas de Porto Alegre).
2.3. Statistical analyses
The sample size was calculated to obtain a power of 80%, α
error of 5%, and 30% reduction of the CRP levels with the FO
supplementation. The statistical analyses were performed
using the SPSS software 16.0 version forWindows (Chicago, IL,
USA). The continuous variables are shown as the means ± SD.
The comparisons of the continuous variables between the
groups were performed using a mixed-model analysis and an
analysis of variance. The categorical variables were analyzed
using the χ2 or Fisher exact tests. The asymmetric variables
were logarithmically transformed and compared using the
Wilcoxon Mann-Whitney U test. The correlations were
calculated using Pearson or Spearman correlation coefficients.
P < .05 was considered statistically significant.3. Results
A total of 160 patients were randomized at a 1:1 ratio to
receive FO (80 patients) or MO (80 patients) for 120 days.
There were 15 exclusions after the randomization and
before the study's initiation. Another 31 exclusions occurred
during the therapy period; thus, 114 patients completed the
study. The timing and explanations for the excluded
patients are shown in Fig. 1. There was no significant
difference in the comparisons of the exclusion causes
between the groups (P = .34). Among the analyzed in-
dividuals, there were 75 men (52%) and 116 whites (80%).
The mean age of the subjects was 59.3 ± 12.8 years, and
the mean body mass index (BMI) values were 25.6 ± 3.2. The
demographic and laboratory data were analyzed at the
Fig. 1 – Numbers of patients in each phase of the study and respective causes for exclusion.
Table 1 – Demographics and baseline measurements in
the study patients
Parameter FO group
(n = 70)
MO group
(n = 75)
P
Male (%) 39 (55.7) 46 (61.3) .694
Race (% white) 67 (95.7) 70 (93.3) .623
Age (y) a 55.7 ± 13.0 58.3 ± 14.8 .338
Time on HD (mo) b 28.5 (14-59.5) 34.5 (16.2-72) .507
BMI (kg/m2) a 25.1 ± 3.47 24.2 ± 4.27 .212
DM (%) 36 (51.4) 34 (45.3) .220
CRP (mg/L) b 8.0 (2.3-16.8) 4.4 (2.3-7.6) .014
Ht (%) a 34.2 ± 4.93 33.8 ± 4.97 .653
Hb (g/dL) a 11.2 ± 1.55 10.9 ± 1.57 .494
URRa 70.0 ± 9.89 71.9 ± 6.97 .259
Kt/Va 1.46 ± 0.34 1.55 ± 0.32 .202
Ca (mg/dL) a 8.43 ±1.04 8.22 ± 0.92 .220
PO4 (mg/dL) b 5.1 (4.08-6.83) 5.0 (3.83-7.08) .838
Cholesterol (mg/dL) a 193.2 ± 58.0 165.9 ±46.4 .017
HDL (mg/dL) a 30.8 ±7.56 34.4 ± 14.3 .591
LDL (mg/dL) a 121 ±45.8 94.5 ± 32.5 .243
TG (mg/dL) b 177 (128-266) 163.5 (112-205) .178
Abbreviations: DM, diabetes mellitus; HT, hematocrit; Hb,
hemoglobin; Ca, calcium; PO4, phosphorus; TG, triglycerides.
a Values at baseline are expressed as means ± SD.
b Values at baseline are expressed as median and range.
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group (Table 1); the group of patients randomized for the FO
group presented significantly higher CRP values (P = .014)
and significantly lower total cholesterol values (P = .007).
The laboratory data were collected at baseline for 145
patients due to intention to treat.
In the initial analysis, inflammation was present in 89
(61%) of the 145 patients. A statistically significant correlation
was found between the BMI and baseline CRP (Rs = 0.22; P =
.022), whereas a negative correlation with similar strength
was found between the HDL cholesterol (HDL-c) and baseline
CRP levels (Rs = −0.23; P = .032).
In the FO group, the comparison between the first and the
last analyses displayed a statistically significant decrease in
the CRP (P < .001), total cholesterol (P = .004), and low-density
lipoprotein (LDL) cholesterol (P = .001) values and an increase
in the HDL-c (P = .004) values; yet, similar findings were not
observed in the MO group (Table 2). Throughout the study, we
observed that the CRP variation in the FO group was higher
than that observed for the MO group (P < .001). In this
interaction assessment, the decrease in the CRP values for
the FO group reached a statistical significance (time 1 × time
2 and 3), whereas the values for theMO group remained stable
(Fig. 2). In the mixed-model analysis, the FO group achieved a
significant reduction in the CRP values when compared with
the MO group (P = .018).
In another approach, by comparing the initially inflamed
with the noninflamed groups, we observed lower urea
reduction ration (URR) and Kt/V (“dialysis dose”) values for
the inflamed group (P < .01). These individuals also presented
a higher BMI mean (P = .03), but the comparisons of the other
study variables did not present statistically significant differ-
ences (Table 3). Moreover, in the FO group, a decrease in the
percentage of inflamed patients was observed throughout the
study, falling from 36.3% to 23.9% to 21.2%, respectively, at
times 1, 2, and 3 (P = .004). In contrast, no statisticallysignificant differences were observed in the respective times
of assessment for the MO group (P = .487).
A further analysis was performed by separating the effects
of intervention in the inflamed and noninflamed groups.
Among the noninflamed patients, neither intervention pro-
duced a significant decrease in the CRP levels (FO 1.26 ± 1.25 to
0.68 ± 1.49 and MO 2.14 ± 1.15 to 2.33 ± 1.28; P, nonsignificant).
Conversely, as shown in Fig. 3, a statistically significant
decrease in the CRP levels was observed in the group of
inflamed patients who received FO (P < .001); however, the
Table 2 – Baseline and 120 days measurements in the study patients
Parameter Baseline 120 d P Baseline 120 d P
FO group (n = 70) MO group (n = 75)
CRP (mg/L) a 8.1 (4.9-19.5) 4.2 (1.7-8.5) <.001 4.4 (2.4-7.5) 3.7(1.3-9.0) .337
Ht (%) b 34.2 ± 4.93 33.9 ± 5.7 .705 33.8 ± 4.97 34.1 ± 5.26 .769
Hb (g/dL) b 11.2 ± 1.55 10.9 ± 1.9 .461 11.0 ± 1.57 10.9 ±1.62 .951
URR b 70.0 ± 9.89 69.2 ± 8.74 .536 71.9 ± 6.97 71.5 ± 8.91 .608
Kt/V b 1.46 ± 0.34 1.43 ± 0.33 .443 1.55 ± 0.32 1.47 ± 0.33 .05
Ca (mg/dL) b 8.43 ± 1.04 8.1 ± 1.12 .055 8.22 ± 0.92 8.43 ± 0.95 .084
PO4 (mg/dL) a 5.1 (4.08-6.83) 4.8 (3.75-6.0) .08 5.0 (3.83-7.08) 4.55 (3.42-5.47) .06
Cholesterol (mg/dL) b 193.2 ± 58.0 178.6 ± 44.4 .004 165.9 ± 46.4 162.5 ± 40.7 .588
HDL (mg/dL) b 30.8 ± 7.56 33.3 ± 8,79 .004 34.4 ± 14.3 35.0 ± 15.1 .591
LDL (mg/dL) b 121.0 ± 45.8 107.6 ± 31.7 .001 94.5 ± 32.5 88.7 ± 35.3 .243
TG (mg/dL) a 177 (128-266) 147 (111-231) .06 163.5 (112-205) 184 (127-249) .05
a Values are expressed as median and range.
b Values are expressed as means ± SD.
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statistically not significant.4. Discussion
In spite of the significant advances in RRT technology,
particularly in regard to HD equipment and techniques,
uremic patients continue to have a highmortality rate, mainly
due to cardiovascular events [20−22]. The traditional risk
factors for cardiovascular mortality include hypertension,
congestive heart failure, dyslipidemias, diabetes, and smok-
ing. More recently, inflammation, oxidative stress, hyperho-
mocysteinemia, and malnutrition have also been associated
with the cardiovascular risk profile for mortality in theseMO groupFO group
m
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Fig. 2 – C-reactive protein (milligrams per liter) variation at
3 time points of assessment. Box and whisker plots showing
medians (horizontal line) P 25-75 (box) and P 10-90 (bars) and
outliers (circles). In the FO group, the decrease in the CRPwas
statistically significant (CRP 1 × CRP 2 and CRP 3). In the MO
group, there was no statistically significant difference in
the comparisons. P 25-75 = median 25th to 75th percentile;
P 10-90 = 10th to 90th percentile.patients [23−25]. Furthermore, certain risk factors specifically
related to uremia are currently recognized and include
divalent ion disturbances, anemia, a chronic hypervolemic
state, and coronary calcification [26−28]. Several studies
reported that chronic inflammation has an elevated preva-
lence in the uremic population [29,30]. The observation that
inflammation is strongly related to the atherogenic process
was reported in both renal and nonrenal patients, and it was
demonstrated that the inflammatory process contributes to
increasedmorbidity andmortality in chronic HD patients [30].
The causes of inflammation in HD patients are complex and
multifactorial, including blood exposure to the dialysis
membranes and water, clinical or subclinical infection of the
vascular access port, malnutrition, reduced levels of antiox-
idants, and increased oxidative stress [31].
The CRP level reflects the generation of proinflammatory
cytokines, such as interleukins (ILs) 1 and 6 and tumor
necrosis factor α (TNF-α), which are elevated in a significantTable 3 – Comparison of demographics andmeasurements
of study patients grouped as inflamed and not inflamed
Parameter Inflamed
(n = 89)
Not inflamed
(n = 56)
P
Age (y) a 57.2 ± 14.1 57.1 ± 14.1 .976
Time on HD (mo) b 26 (13.3-71) 37 (23-67.5) .142
White (%) 71 (80.8) 45 (81.7) .141
Male (%) 48 (54.2) 23 (42.2) .554
BMI (kg/m2) a 25.5 ± 3.94 23.3 ± 3.27 .03
CRP (mg/L) b 9 (6.7-20.0) 2.2 (1.45-3.55) <.001
Ht (%) a 32.9 ± 4.78 34.1 ± 5.09 .816
Hb (g/dL) a 11.0 ± 1.53 11.1 ± 1.60 .624
URRa 70.0 ± 9.89 73.5 ± 6.62 <.01
Kt/Va 1.44 ± 0.32 1.60 ± 0.32 <.01
Ca (mg/dL) a 8.43 ± 1.04 8.23 ± 1.02 .20
PO4 (mg/dL) b 5.25 (4.2-6.88) 4.8 (3.75-7.05) .306
Cholesterol (mg/dL) a 178.0 ± 52.4 183.4 ± 56.7 .653
HDL (mg/dL) a 31.7 ± 11.8 33.7 ± 10.9 .436
LDL (mg/dL) a 105.9 ± 39.7 110.1 ± 47.2 .662
TG (mg/dL) b 155 (102.5-209) 157.5 (124.2-250.2) .377
Difference in the comparisons.
a Values are expressed as means ± SD.
b Values are expressed as median and range.
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Fig. 3 – C-reactive protein variation at the beginning and at
the end of the study period. Assessment of inflamed subjects
according to intervention. Box and whisker plots showing
medians (horizontal line) P 25-75 (box) and P 10-90 (bars) and
outliers (circles). In the FO group, the decrease in the CRPwas
statistically significant (P < .001). In the MO group, the
reduction of CRP levels is not statistically significant.
P 25-75 = median 25th to 75th percentile; P 10-90 = 10th to
90th percentile.
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considered to be predictors ofmortality in this population [32].
High levels of acute-phase proteins, such as CRP, are directly
linked to atherogenic properties and may intensify the
accelerated atherogenesis observed in patients undergoing
HD [27,33]. Perhaps the main contributors to the elevated
frequency of inflammation in this population are the expo-
sure of the blood to bioincompatible extracorporeal circuits,
including the dialysis filters and lines, and exposure to
nonsterile dialysis water and solutions [1].
The 2 physiologically essential and complementary fatty
acids in humans are linoleic acid [18:2 (n-6)] from the n-6 family
and αLNA from the n-3 family [18:3 (n-3)] [16,34,35]. InWestern
cultures, the effects of an inadequate intake of α-linolenic fatty
acid compared with linoleic fatty acids are aggravated by the
reduced conversion from the n-3 active products. This is due to
the elevated intake of linoleic fatty acids and their competition
for the conversion enzymes, namely, cyclooxygenase and
lipoxygenase, at the cell membranes [35]. As a result, there is
an overproduction of proinflammatory series 2 eicosanoid-like
prostaglandins and series 4 leukotrienes compared with the
noninflammatory series 3 prostaglandins and series 5 leuko-
trienes, which have anti-inflammatory, antiaggregatory, and
vasodilatation properties [36−38].
Murakami et al [39] examined the associations between the
dietary intake total n-3 polyunsaturated fatty acid and serum
CRP concentrations and found an independent inverse
association for both factors in a group of young Japanesewomen. Furthermore, considering the difficulties of consum-
ing these nutrients through food and the uncertainties in
terms of the absorption of α-linolenic fatty acid, many studies
have been conducted to evaluate this fatty acid as a
supplement and its impact on human health using different
regimens and populations [40−42]. The effects on the preven-
tion of atherosclerosis, chronic hepatitis, psoriasis, rheuma-
toid arthritis, myocardial infarction, asthma, and diabetes
were described, and several studies demonstrated a decrease
in proinflammatory cytokines [34−36,40,41]. Lopez-Garcia [43]
observed a 29% decrease of serumCRP in a retrospective study
that evaluated the uptake of αLNA through food in healthy
women. Using short-term fish oil supplementation, Ciubotaru
et al [44] found a 35% decrease of the CRP levels in
postmenopausal women. In studies with healthy volunteers
and patients with rheumatoid arthritis receiving FO and fish
oil, control of inflammation was observed as reflected by a
decrease in the mediators of the inflammatory process
(cytokines, TNF-α, and IL-1β) [44].
Flaxseed oil does not contain EPA and DHA fatty acids but is
rich in their precursor, αLNA. α-Linolenic acid is partially
converted to longer chain n-3 polyunsaturated fatty acids,
such as EPA (20:5n3) and DHA (22:6n-3); however, at present, it
is not known what portion of αLNA undergoes these conver-
sions in the plasma, cells, and tissues [45]. The hypothesis that
the α-linolenic fatty acid present in FO is able to reduce
inflammation in humans is supported by many studies. The
effect of an FO-based diet on the synthesis of TNF-α and IL-1β
was tested in healthy volunteers. Over a 4-week period, it was
observed that its use inhibited the production of these
inflammatory factors by approximately 30%, demonstrating
its role as a potential inhibitor of these mediators [40]. Jenkins
et al [19] suggested that the intake of grain flaxseed or FO
decreases total cholesterol andHDL-c in humans. The effects of
FO are mainly observed with regard to LDL cholesterol levels,
with the levels of HDL-c and triglycerides being unchanged [46].
Lastly, Singer et al [47] reported a decrease in serum lipids with
FO supplementation in patients with primary hyperlipidemia.
Surprisingly, there are few studies that have tested
therapeutic interventions in the control of the inflammatory
state in high-risk populations of uremic patients [14,42].
Considering the use of FO in other situations, the absence of
significant side effects, the easy access and clinical applica-
bility, the anti-inflammatory and antilipemic activity, and the
beneficial effects observed in other situations on cardiovas-
cular risk factors, we hypothesized that this agent could be
useful in reducing the microinflammatory state in uremic
subjects undergoing RRT with HD. In the present study, we
observed that 4 months of FO supplementation appears to
reduce the CRP levels in an early and sustained fashion.
Interestingly, those patients who were previously inflamed
seemed to have had better therapeutic results. Furthermore, a
better response was observed in the lipid profile of the
individuals supplemented with FO between the first and
third periods of the study when compared with the placebo
group. These data corroborate the studies conducted with n-3
fatty acids in their bioactive configuration (DHA and EPA) and
may suggest that the amounts of αLNA converted into DHA
and EPA are sufficient to obtain anti-inflammatory and
antilipemic effects.
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mainly due to the fact that the group of patients that received
FO had higher CRP levels than the placebo group before the
onset of the study, a situation that occurred because of a
flawed randomization. Other limitations include the number
of patients and the short-termduration of the study. However,
as an exploratory study, we believe that these limitations do
not invalidate the findings. Further supporting our results, we
observed that the trend was significant in the patients who
received the FO supplementation and did not occur in the
placebo group by evaluating the changes in the inflammatory
and noninflammatory state.
The results presented here support the hypothesis that FO
and perhaps other anti-inflammatory therapies may have
beneficial effects on the CRP levels in chronic HD patients. Our
findings must be confirmed in different cohorts of uremic
subjects. If the beneficial effect is confirmed, studies must be
designed to optimize the doses and lengths of administration
and to test the therapeutic efficiency on more relevant
outcomes, such as cardiovascular and cerebrovascular events
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